<DOC>
	<DOC>NCT01012908</DOC>
	<brief_summary>The primary objective of this clinical trial is to demonstrate non-inferiority clinical development of pancreatic enzymes from Laboratory Bergamo (Norzyme ®) in relation to pancreatic enzymes from Solvay Pharmaceuticals (Creon ®), by comparing the average amount of lipids in the feces of 72 hours after 14 days of treatment with each drug.</brief_summary>
	<brief_title>Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency</brief_title>
	<detailed_description>As a secondary objective will be assessed the following parameters: - Incidence of abdominal pain; - Frequency of flatus; - Frequency of bowel movements during the treatment; - Consistency of stools during treatment; - Amount of medication used among the treatments. All these parameters will be measured based on reports of patients in a specific diary.</detailed_description>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Patients must agree with the purposes of the study and sign the Informed Consent in two ways; Be aged over 18 years; Display chronic exocrine pancreatic insufficiency due to chronic pancreatic, post surgical or other situation that leads to severe glandular disease; Doing controlled clinical treatment of enzyme replacement with Creon ® 25,000 (or similar with the same concentration of lipase) during meals; Agree to record daily food intake in phase 2 and repeat the diet in phase 3; Present ability to meet the patient's diary; Be clinically compensated with replacement therapy; Must be admitted patients in both the sexes; Must be accepted patients of any ethnicity. Cystic fibrosis; Acute pancreatitis; Participation in any experimental study or ingestion of any experimental drug in the 12 months preceding the study; Diabetes decompensated; Regular use of medications that interfere with the action of the drug test: the 4 weeks preceding the study or any medication that interferes with the drug test a week before the start of the study; Any type of treatment for morbid obesity; Abusive use of alcohol in the three months preceding the study; Pregnancy and lactation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>